<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13239">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01855607</url>
  </required_header>
  <id_info>
    <org_study_id>AAAL2664</org_study_id>
    <nct_id>NCT01855607</nct_id>
  </id_info>
  <brief_title>Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy</brief_title>
  <official_title>Topical Menthol for CIPN: a Randomized, Placebo Controlled Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess whether six week treatment with twice a day topical Menthol application will
      decrease persistent neuropathic pain from chemotherapy among breast and colorectal cancer
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess whether six week treatment with BID topical Menthol application will decrease
      persistent neuropathic pain as measured by the change in Brief Pain Inventory-Short Form
      (BPI-SF worst pain score), following neoadjuvant/adjuvant chemotherapy with taxanes or
      oxaliplatin-based regimens among breast and colorectal cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>neuropathic pain</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured by BPI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>functional tests</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>grooved pegboard and vibrometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>topical menthol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical menthol cream to hands and feet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical cream without menthol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>topical menthol</intervention_name>
    <arm_group_label>topical menthol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo cream</intervention_name>
    <arm_group_label>placebo cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age&gt;21 years

          2. History of stage I-III breast or colorectal cancer

          3. Patient has to have completed adjuvant or neo-adjuvant Taxane based breast cancer
             therapy or Oxaliplatin based colon cancer chemotherapy between one and 24 months
             prior to registration

          4. Signed informed consent

          5. Concomitant biologic, hormonal or radiation therapy are acceptable.

          6. Narcotics, antidepressants or other medications for the treatment of CIPN are
             permitted, if patient on a stable dose for at least one month prior to enrollment.

          7. Pain as defined by BPI worst pain greater than or equal to a 5 out of 10.

          8. CIPN as defined  by experiencing neuropathy (numbness, tingling, thermal hyperalgesia
             or cold allodynia) in the hands and feet frequently or most of the time in the past
             seven days.

        Exclusion Criteria:

          1. Previous treatment with topical menthol (menthol/methylsalicylate products like
             BenGay, Aspercreme, or Icy Hot) of any concentration within the previous 3 months

          2. Known diabetic neuropathy

          3. Severe concomitant illnesses

          4. Known allergy or preexisting skin disease which prohibits use of menthol

          5. Any topical treatment for neuropathy or other serious skin condition on the hands or
             feet.

             -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Hershman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dawn L Hershman, MD</last_name>
    <phone>212 305-1945</phone>
    <email>dlh23@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Man Chi Ngan</last_name>
    <phone>212 304-5580</phone>
    <email>mn2527@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Man Chi Ngan</last_name>
      <phone>212-305-5580</phone>
    </contact>
    <investigator>
      <last_name>Katherine Crew, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dawn Hershman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 30, 2013</lastchanged_date>
  <firstreceived_date>May 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Dawn L. Hershman</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>chemotherapy induced neuropathy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
